Photo: Tyler Frew MD / Wikimedia Commons, CC BY-SA 4.0, cropped
Pacira Soared 44% in One Day After Viatris Offered $36.50 a Share. Should You Hunt for the Next Buyout?
- Viatris agreed to buy Pacira BioSciences for $36.50 per share in cash, announced October 8, 2026.
- The deal is worth about $1.65 billion, roughly 45% above Pacira's previous close.
- Pacira shares rose 44%, up $11.19 to $36.39. That's 11 cents below the offer.
- Viatris shares fell nearly 3%.
- Viatris will buy the shares through a tender offer and expects to finish by the end of 2026.
What happened
On Thursday, October 8, the drug company Viatris said it will buy Pacira BioSciences for $36.50 a share in cash.
Pacira had closed the day before at about $25. By Thursday's close it was $36.39, up 44%.
| Offer | $36.50 per share, cash |
| Deal value | About $1.65 billion |
| Premium | About 45% |
| Pacira's close on October 8 | $36.39 (+44%) |
| Viatris's move | Down nearly 3% |
| Expected to close | By the end of 2026 |
What Viatris is buying
Pacira focuses on one thing: controlling pain without opioids.
Its main product, Exparel, is a long-lasting numbing drug that surgeons inject during an operation. It keeps working for days, so patients need fewer opioid painkillers afterward. Pacira also sells Zilretta, an injection for knee arthritis, and iovera, a device that uses cold to quiet nerves.
Viatris is a large maker of generic and off-patent medicines. It was formed in 2020 from Mylan and a division of Pfizer. Generic drugs are a low-growth business, so Viatris has been looking for branded products it can sell through the hospital relationships it already has.
Three buyouts in one week, three different reactions
This was the third big takeover of the week. Line them up and you can see how the terms shape the price.
| Target | Paid in | Expected close | Gap to the offer |
|---|---|---|---|
| Pacira | Cash | End of 2026 | About 0.3% |
| PTC | Cash | By Q3 2027 | About 6% |
| RXO | Cash and stock | First half of 2027 | Moves with the buyer's stock |
Pacira's gap is tiny because the deal is small, all cash and fast. PTC's is wider because it needs a year and a national security review. RXO's payout isn't even fixed.
The longer the wait and the more that can go wrong, the bigger the gap.
How a tender offer works
Viatris isn't waiting for a shareholder vote. It's using a tender offer:
- Viatris publicly offers $36.50 for every share.
- Shareholders "tender" their shares, which means agreeing to sell. Your broker will send you a notice.
- Once enough shares are tendered, Viatris buys the rest at the same price through a merger.
If you do nothing, you still end up with $36.50 a share in cash. It just arrives a little later.
If you own Pacira
With the stock 11 cents below the offer, there's almost nothing left to gain by waiting. The choice is mostly about taxes and convenience:
- Sell now and you control the timing.
- Wait and the cash arrives when the deal closes, probably in the same tax year anyway.
In a taxable account, either way is a sale and your gain is taxable.
Should you go looking for the next one?
A 44% gain in a day is hard to ignore. Before you start screening for small drug companies, look at the odds.
- You can't know in advance. Anyone who truly knows a bid is coming isn't allowed to trade on it.
- Rumoured targets usually disappoint. Most never get an offer, and the stock drifts down as hope fades.
- Small drug stocks are risky by themselves. A single failed trial or weak sales report can cut the price in half. See biotech's all-or-nothing days.
- Pacira was no sure thing. The offer is far below prices the stock reached in earlier years.
Here's a better way to think about it. Thousands of companies trade on US exchanges. A few get bought every month at a big premium. If you own a total market index fund, you own all of them. You collected a sliver of the Pacira, PTC and RXO premiums this week without picking anything.
That's the quiet case for index funds over stock picking.
Frequently asked questions
Why did Pacira BioSciences stock go up 44%?
Viatris announced on October 8, 2026 that it will buy Pacira for $36.50 per share in cash. That was about 45% above the previous day's closing price, so the stock rose to just under the offer and closed at $36.39.
What does Pacira BioSciences make?
Pacira makes non-opioid treatments for pain. Its main product is Exparel, a long-acting local anaesthetic injected during surgery to control pain afterward. It also sells Zilretta, an injection for knee osteoarthritis pain, and the iovera system, which uses cold to block pain signals.
What happens to Pacira shareholders?
Viatris will make a tender offer, which is a formal request to buy shares at $36.50 each. Shareholders who accept receive cash. Any shares not tendered are then bought at the same price through a merger. After that, Pacira stops trading on Nasdaq.
Why did Pacira close so close to the offer price?
The stock closed 11 cents below $36.50 because the deal is all cash, both boards approved it, and it is expected to close within about three months. A short wait and a low risk of failure mean a very small gap.
Can I make money buying stocks before they get acquired?
It is very hard. Takeovers are announced without warning and trading on inside knowledge of one is illegal. Stocks that are rumoured targets often fall when no bid arrives. A broad index fund owns thousands of companies, so it captures takeover premiums without having to guess.
Primary sources
- Seeking Alpha — Pacira BioSciences jumps 44% on Viatris acquisition deal (Oct. 8, 2026)
- Benzinga — Viatris bets big on non-opioid painkillers with Pacira buyout
- The Motley Fool — Why Pacira BioSciences skyrocketed today (Oct. 8, 2026)
- GuruFocus — Viatris to acquire Pacira BioSciences at $36.50 per share
Data & disclaimer: This article is for educational purposes only and is not financial or investment advice. Figures reflect data available as of Oct 9, 2026, and conditions change — always confirm current pricing, rates and rules with the provider before you act. Written by Elizabeta Dimoska. See our editorial standards and disclosure.
Comments